Pell Bio-Med Technology Co., Ltd. (TPE:6949)
Taiwan · Delayed Price · Currency is TWD 687.00
-29.00 (-4.05%)
May 15, 2026, 1:30 PM CST
Pell Bio-Med Technology Revenue
Pell Bio-Med Technology had revenue of 6.37M TWD in the quarter ending March 31, 2026, a decrease of -46.68%. This brings the company's revenue in the last twelve months to 25.85M, down -2.74% year-over-year. In the year 2025, Pell Bio-Med Technology had annual revenue of 31.42M with 60.07% growth.
Revenue (ttm)
25.85M
Revenue Growth
-2.74%
P/S Ratio
1,812.72
Revenue / Employee
n/a
Employees
n/a
Market Cap
46.86B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 31.42M | 11.79M | 60.07% |
| Dec 31, 2024 | 19.63M | 1.60M | 8.86% |
| Dec 31, 2023 | 18.03M | 876.00K | 5.11% |
| Dec 31, 2022 | 17.16M | 3.18M | 22.75% |
| Dec 31, 2021 | 13.98M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Sunmax Biotechnology | 2.03B |
| EirGenix | 1.01B |
| Medigen Vaccine Biologics | 613.17M |
| TaiMed Biologics | 601.19M |
| Oneness Biotech | 140.52M |
| Polaris Group | 40.60M |
| Caliway Biopharmaceuticals | 38.04M |
| AP Biosciences | 32.25M |